PIK3CA and lymphatic malformation: Mice containing these Pi3kca mutations exhibit many of the same pathologies as humans with lymphatic malformations, which were attenuated with alpelisib, a Food and Drug Administration (FDA)-approved PI3K inhibitor for breast cancer patients (102).